title: Cystic Fibrosis: Microbiology and Host Response.
abstract: The earliest descriptions of lung disease in people with cystic fibrosis (CF) showed the involvement of 3 interacting pathophysiologic elements in CF airways: mucus obstruction, inflammation, and infection. Over the past 7 decades, our understanding of CF respiratory microbiology and inflammation has evolved with the introduction of new treatments, increased longevity, and increasingly sophisticated laboratory techniques. This article reviews the current understanding of infection and inflammation and their roles in CF lung disease. It also discusses how this constantly evolving information is used to inform current therapeutic strategies, measures and predictors of disease severity, and research priorities.
authors.affiliation: Children's Hospital Colorado, University of Colorado School of Medicine, 13123 East 16th Avenue, B-395, Aurora, CO 80045, USA.
authors.forename: Edith T
authors.initials: ET
authors.lastname: Zemanick
authors.affiliation: Departments of Pediatrics and Microbiology, Seattle Children's Hospital and University of Washington, 4800 Sand Point Way Northeast, MS OC.7.720, Seattle, WA 98105, USA. Electronic address: lhoffm@uw.edu.
authors.forename: Lucas R
authors.initials: LR
authors.lastname: Hoffman
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000382:microbiology* / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology*; D008171:Lung Diseases / Q000209:etiology / Q000382:microbiology*; D012141:Respiratory Tract Infections / Q000209:etiology / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents
keywords: Biomarker; Cystic fibrosis; Infection; Inflammation; Microbiology; Neutrophil